Guidelines for the evolving landscape of liver disease: From viral hepatitis to MAFLD.
作者信息
Elangovan Harendran, George Jacob
机构信息
Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, NSW, Australia.
出版信息
Chin Med J (Engl). 2025 May 5;138(9):1013-1015. doi: 10.1097/CM9.0000000000003616. Epub 2025 Mar 26.
Abstract
摘要
相似文献
1
Guidelines for the evolving landscape of liver disease: From viral hepatitis to MAFLD.肝病不断演变格局的指南：从病毒性肝炎到代谢相关脂肪性肝病。
Chin Med J (Engl). 2025 May 5;138(9):1013-1015. doi: 10.1097/CM9.0000000000003616. Epub 2025 Mar 26.
2
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis.代谢功能障碍相关脂肪性肝病（MAFLD）与病毒性肝炎
J Clin Transl Hepatol. 2022 Feb 28;10(1):128-133. doi: 10.14218/JCTH.2021.00200. Epub 2021 Oct 8.
3
The interplay of metabolic dysfunction-associated fatty liver disease and viral hepatitis on liver disease severity: A large community-based study in a viral endemic area.代谢功能障碍相关脂肪性肝病与病毒性肝炎对肝脏疾病严重程度的相互作用：病毒流行地区的一项大型基于社区的研究。
J Gastroenterol Hepatol. 2024 Jan;39(1):193-201. doi: 10.1111/jgh.16363. Epub 2023 Sep 20.
4
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.双重病因性 MAFLD：乙型肝炎病毒、丙型肝炎病毒、酒精与 MAFLD 之间的相互作用。
Hepatol Int. 2024 Oct;18(Suppl 2):897-908. doi: 10.1007/s12072-024-10699-x. Epub 2024 Aug 8.
5
Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.糖尿病合并 MAFLD 与慢性病毒性肝炎患者肝细胞癌风险增加和死亡率升高相关。
Int J Cancer. 2023 Oct 15;153(8):1448-1458. doi: 10.1002/ijc.34637. Epub 2023 Jul 13.
6
Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis.非侵入性血清标志物在预测伴有或不伴有病毒性肝炎的 MAFLD 患者肝纤维化中的表现。
Kaohsiung J Med Sci. 2024 Apr;40(4):374-383. doi: 10.1002/kjm2.12804. Epub 2024 Jan 17.
7
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.MAFLD改善了亚太地区肝脏疾病的临床实践。
Clin Mol Hepatol. 2022 Apr;28(2):150-163. doi: 10.3350/cmh.2021.0310. Epub 2021 Nov 10.
8
[Analysis of clinical and pathological features of chronic hepatitis B combined with metabolic-associated fatty liver disease].慢性乙型肝炎合并代谢相关脂肪性肝病的临床及病理特征分析
Zhonghua Gan Zang Bing Za Zhi. 2023 Feb 20;31(2):126-132. doi: 10.3760/cma.j.cn501113-20220701-00362.
9
[Analysis of clinical characteristics and risk factors of hepatic fibrosis in children with chronic hepatitis B combined with metabolic-related fatty liver disease].[慢性乙型肝炎合并代谢相关脂肪性肝病患儿肝纤维化的临床特征及危险因素分析]
Zhonghua Gan Zang Bing Za Zhi. 2023 Jun 20;31(6):601-607. doi: 10.3760/cma.j.cn501113-20220905-00458.
10
The importance and impact of recognizing metabolic dysfunction-associated fatty liver disease in patients with chronic hepatitis C.认识到慢性丙型肝炎患者代谢功能障碍相关脂肪性肝病的重要性和影响。
J Dig Dis. 2022 Jan;23(1):33-43. doi: 10.1111/1751-2980.13071.
本文引用的文献
1
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024).《代谢功能障碍相关脂肪性肝病防治指南（2024年版）》
J Clin Transl Hepatol. 2024 Nov 28;12(11):955-974. doi: 10.14218/JCTH.2024.00311. Epub 2024 Nov 4.
2
Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population.整合多组学分析确定了中国人群非酒精性脂肪性肝病的不同分子亚型。
Sci Transl Med. 2024 Nov 6;16(772):eadh9940. doi: 10.1126/scitranslmed.adh9940.
3
acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study.用于诊断纤维化性MASH及预测肝脏相关事件的acFibroMASH指数：一项国际多中心研究
Clin Gastroenterol Hepatol. 2025 Apr;23(5):785-796. doi: 10.1016/j.cgh.2024.07.045. Epub 2024 Oct 2.
4
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women.炎症、胆固醇、脂蛋白(a)与女性30年心血管结局
N Engl J Med. 2024 Dec 5;391(22):2087-2097. doi: 10.1056/NEJMoa2405182. Epub 2024 Aug 31.
5
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).EASL-EASD-EASO 临床实践指南：代谢功能障碍相关脂肪性肝病（MASLD）的管理。
J Hepatol. 2024 Sep;81(3):492-542. doi: 10.1016/j.jhep.2024.04.031. Epub 2024 Jun 7.
6
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
7
Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia.运动在代谢相关脂肪性肝病（MAFLD）成人管理中的作用：来自澳大利亚运动与运动科学学会的立场声明。
Sports Med. 2023 Dec;53(12):2347-2371. doi: 10.1007/s40279-023-01918-w. Epub 2023 Sep 11.
8
Exploring the landscape of steatotic liver disease in the general US population.探索美国普通人群中的脂肪性肝病情况。
Liver Int. 2023 Nov;43(11):2425-2433. doi: 10.1111/liv.15695. Epub 2023 Aug 17.
9
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
10
Physical activity, diet quality and all-cause cardiovascular disease and cancer mortality: a prospective study of 346 627 UK Biobank participants.体力活动、饮食质量与全因心血管疾病及癌症死亡率：对346627名英国生物银行参与者的前瞻性研究
Br J Sports Med. 2022 Jul 10. doi: 10.1136/bjsports-2021-105195.
Zotero 插件